Drug Interaction Report
1 potential interaction and/or warning found for the following 2 drugs:
- metipranolol ophthalmic
- pasireotide
Interactions between your drugs
metipranolol ophthalmic pasireotide
Applies to: metipranolol ophthalmic, pasireotide
MONITOR: The risk of significant bradycardia and atrioventricular (AV) block may be increased during concomitant treatment of pasireotide with other drugs that slow heart rate or AV conduction such as beta-blockers, calcium channel blockers, atazanavir, digitalis, flecainide, lacosamide, mefloquine, moricizine, and propafenone.
MANAGEMENT: Pasireotide has not been studied in patients receiving other bradycardic drugs. Because bradycardia and AV block are recognized risk factors for torsade de pointes arrhythmia, electrocardiographic monitoring is recommended prior to initiation of pasireotide and during treatment. Dose adjustments of beta blockers and calcium channel blockers or correction of electrolyte disturbances may be necessary.
References (5)
- (2001) "Product Information. Exelon (rivastigmine)." Novartis Pharmaceuticals
- Cerner Multum, Inc. "UK Summary of Product Characteristics."
- Canadian Pharmacists Association (2006) e-CPS. http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink
- Cerner Multum, Inc. "Australian Product Information."
- (2013) "Product Information. Signifor (pasireotide)." Novartis Pharmaceuticals
Drug and food interactions
No alcohol/food interactions were found with the drugs in your list. However, this does not necessarily mean no food interactions exist. Always consult your healthcare provider.
Therapeutic duplication warnings
No duplication warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
Report options
- Switch to consumer interaction data
- Email this report to a friend, doctor, or patient
- Ask questions, find answers
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
See also:
Lumigan
Lumigan is used to treat open angle glaucoma. Learn about side effects, interactions and indications.
Xalatan
Xalatan (latanoprost) is used to treat certain types of glaucoma. Includes Xalatan side effects ...
Ubrelvy
Ubrelvy (ubrogepant) tablets are used for the acute treatment of migraine. Includes Ubrelvy side ...
Cosopt
Cosopt reduces the amount of fluid in the eye and is used to treat glaucoma. Learn about side ...
Combigan
Combigan (brimonidine and timolol) is used to treat glaucoma or ocular hypertension. Includes ...
Alphagan P
Alphagan P is used to treat glaucoma or ocular hypertension (high pressure inside the eye). Learn ...
Vyzulta
Vyzulta is used for glaucoma, open angle, glaucoma/intraocular hypertension
Rhopressa
Rhopressa is used for glaucoma, open angle, intraocular hypertension
Simbrinza
Simbrinza (brimonidine and brinzolamide) is used to treat open-angle glaucoma or ocular ...
Learn more
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.